GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Shiller PE Ratio

Fortress Biotech (FRA:CNB1) Shiller PE Ratio : (As of May. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech Shiller PE Ratio Historical Data

The historical data trend for Fortress Biotech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Shiller PE Ratio Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fortress Biotech's Shiller PE Ratio

For the Biotechnology subindustry, Fortress Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Shiller PE Ratio falls into.



Fortress Biotech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fortress Biotech's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Fortress Biotech's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Fortress Biotech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.435 100.560 -1.880
201409 -1.513 100.428 -1.985
201412 -1.216 99.070 -1.617
201503 -4.297 99.621 -5.684
201506 -2.138 100.684 -2.798
201509 -6.148 100.392 -8.070
201512 -4.269 99.792 -5.637
201603 -4.176 100.470 -5.477
201606 -4.139 101.688 -5.364
201609 -4.277 101.861 -5.533
201612 -6.257 101.863 -8.094
201703 -4.207 102.862 -5.390
201706 -5.741 103.349 -7.320
201709 -8.432 104.136 -10.670
201712 -2.788 104.011 -3.532
201803 -5.961 105.290 -7.461
201806 -6.420 106.317 -7.957
201809 -4.756 106.507 -5.884
201812 -7.647 105.998 -9.507
201903 0.266 107.251 0.327
201906 -3.186 108.070 -3.885
201909 -2.996 108.329 -3.644
201912 -3.645 108.420 -4.430
202003 -2.579 108.902 -3.121
202006 -2.531 108.767 -3.066
202009 -2.547 109.815 -3.056
202012 -0.740 109.897 -0.887
202103 -1.386 111.754 -1.634
202106 -0.498 114.631 -0.572
202109 -3.315 115.734 -3.774
202112 -5.045 117.630 -5.652
202203 -2.452 121.301 -2.664
202206 -3.689 125.017 -3.888
202209 -4.153 125.227 -4.370
202212 -3.204 125.222 -3.372
202303 -2.942 127.348 -3.044
202306 -3.323 128.729 -3.402
202309 -0.881 129.860 -0.894
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fortress Biotech  (FRA:CNB1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Fortress Biotech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines